Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000085 | 0.91 | CA2 (0.34) | CA2 | |
| Iosimide SCHEMBL898150 | 0.85 | CA2 (0.33) | CA2NTRK2ALPLPOLB | |
| Iosimide SCHEMBL8845588 | 0.85 | CA2 (0.33) | CA2NTRK2ALPLPOLB | |
| SCHEMBL3259093 | 0.78 | LMNA (0.30) | — | |
| SCHEMBL4345180 | 0.78 | — | — | |
| SCHEMBL10305674 | 0.77 | CYP2C19 (0.39) | — | |
| SCHEMBL3786697 | 0.76 | — | — | |
| SCHEMBL11372360 | 0.76 | CA2 (0.32) | CA2 | |
| SCHEMBL28363240 | 0.73 | — | — | |
| SCHEMBL9787642 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | claimed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | claimed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | claimed |
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | claimed |
| EP-2245004-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106551-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | claimed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | claimed |
| US-8535642-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-09-17 | — | — | US | disclosed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | disclosed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | disclosed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | CA2 126/4885NTRK2 3226/4885TSHR 72/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | CA2 126/4885NTRK2 3226/4885TSHR 72/4885 |
| US-20110008263-A1 | CONTRAST AGENTS | C5, C1R, C3AR1 | CA2 438/4885NTRK2 2895/4885TSHR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.